Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

Gurdon, 1971, Use of frog eggs and oocytes for the study of messenger RNA and its translation in living cells, Nature, 233, 177, 10.1038/233177a0 Laskey, 1972, Translation of encephalomyocarditis viral RNA in oocytes of Xenopus laevis, Proc Natl Acad Sci USA, 69, 3665, 10.1073/pnas.69.12.3665 Boczkowski, 1996, Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J Exp Med, 184, 465, 10.1084/jem.184.2.465 Wolff, 1990, Direct gene transfer into mouse muscle in vivo, Science, 247, 1465, 10.1126/science.1690918 Conry, 1995, Characterization of a messenger RNA polynucleotide vaccine vector, Cancer Res, 55, 1397 Jirikowski, 1992, Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA, Science, 255, 996, 10.1126/science.1546298 Alexopoulou, 2001, Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3, Nature, 413, 732, 10.1038/35099560 Diebold, 2004, Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA, Science, 303, 1529, 10.1126/science.1093616 Heil, 2004, Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8, Science, 303, 1526, 10.1126/science.1093620 Hornung, 2006, 5’-Triphosphate RNA is the ligand for RIG-I, Science, 314, 994, 10.1126/science.1132505 Kato, 2006, Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses, Nature, 441, 101, 10.1038/nature04734 Pichlmair, 2006, RIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates, Science, 314, 997, 10.1126/science.1132998 Rehwinkel, 2010, RIG-I detects viral genomic RNA during negative-strand RNA virus infection, Cell, 140, 397, 10.1016/j.cell.2010.01.020 Nallagatla, 2007, 5’-triphosphate-dependent activation of PKR by RNAs with short stem-loops, Science, 318, 1455, 10.1126/science.1147347 Rittig, 2011, Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients, Mol Ther, 19, 990, 10.1038/mt.2010.289 Scheel, 2006, Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA, Eur J Immunol, 36, 2807, 10.1002/eji.200635910 Weide, 2008, Results of the first phase I/II clinical vaccination trial with direct injection of mRNA, J Immunother, 31, 180, 10.1097/CJI.0b013e31815ce501 Weide, 2009, Direct injection of protamine-protected mRNA: results of a phase ½ vaccination trial in metastatic melanoma patients, J Immunother, 32, 498, 10.1097/CJI.0b013e3181a00068 Fotin-Mleczek, 2011, Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity, J Immunother, 34, 1, 10.1097/CJI.0b013e3181f7dbe8 Karikó, 2005, Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA, Immunity, 23, 165, 10.1016/j.immuni.2005.06.008 Anderson, 2011, Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNase L, Nucleic Acids Res, 39, 9329, 10.1093/nar/gkr586 Anderson, 2010, Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation, Nucleic Acids Res, 38, 5884, 10.1093/nar/gkq347 Karikó, 2008, Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability, Mol Ther, 16, 1833, 10.1038/mt.2008.200 Warren, 2010, Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell, 7, 618, 10.1016/j.stem.2010.08.012 Zangi, 2013, Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction, Nat Biotechnol, 31, 898, 10.1038/nbt.2682 Kormann, 2011, Expression of therapeutic proteins after delivery of chemically modified mRNA in mice, Nat Biotechnol, 29, 154, 10.1038/nbt.1733 Karikó, 2012, Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin, Mol Ther, 20, 948, 10.1038/mt.2012.7 Jayaraman, 2012, Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo, Angew Chem Int Ed Engl, 51, 8529, 10.1002/anie.201203263 Martinon, 1993, Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA, Eur J Immunol, 23, 1719, 10.1002/eji.1830230749 Hoerr, 2000, In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies, Eur J Immunol, 30, 1, 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-# Petsch, 2012, Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection, Nat Biotechnol, 30, 1210, 10.1038/nbt.2436 Diken, 2013, mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA, Cancer Immunol Res, 1, 386, 10.1158/2326-6066.CIR-13-0046 Kreiter, 2011, FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines, Cancer Res, 71, 6132, 10.1158/0008-5472.CAN-11-0291 Kreiter, 2010, Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity, Cancer Res, 70, 9031, 10.1158/0008-5472.CAN-10-0699 Schlake, 2012, Developing mRNA-vaccine technologies, RNA Biol, 9, 1319, 10.4161/rna.22269 Pascolo, 2004, Messenger RNA-based vaccines, Expert Opin Biol Ther, 4, 1285, 10.1517/14712598.4.8.1285 Probst, 2007, Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent, Gene Ther, 14, 1175, 10.1038/sj.gt.3302964 Karikó, 2011, Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA, Nucleic Acids Res, 39, e142, 10.1093/nar/gkr695 Cheung, 1998, Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects, Clin Pharmacol Ther, 64, 412, 10.1016/S0009-9236(98)90072-8 McGowan, 2008, Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis, Clin J Am Soc Nephrol, 3, 1006, 10.2215/CJN.05671207 Hope, 2014, Enhancing siRNA delivery by employing lipid nanoparticles, Therapeutic Delivery, 5, 663, 10.4155/tde.14.37 Mays, 2013, Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism, J Clin Invest, 123, 1216, 10.1172/JCI65351 Maier, 2013, Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics, Mol Ther, 21, 1570, 10.1038/mt.2013.124 Coelho, 2013, Safety and efficacy of RNAi therapy for transthyretin amyloidosis, N Engl J Med, 369, 819, 10.1056/NEJMoa1208760 Akinc, 2010, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Mol Ther, 18, 1357, 10.1038/mt.2010.85